Merck & Co Inc
BRIEF: For the nine months ended 30 September 2013, Merck & Co., Inc. revenues decreased 8% to $32.71B. Net income applicable to common stockholders decreased 31% to $3.62B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Restructuring costs increase from $473M to $1.14B (expense), Exchange Gains and Losses increase from $130M to $278M (expense).
Common Stock $.50 Par, 03/11, 6.50B auth., 3,576,948,356 issd., less 491,657,062 shs in Treas. @ $22.32B. Insiders own 0.05%. PO: NA. 2/99, 2-for-1 stock split; 5/92, 5/88, 3-for-1 stock split. FY'01-02 fincls. & '02-03 Qs are restated for discont. ops. FY'04 Qs are reclassified.
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc's Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.